Head and neck cancer: How a simple blood test can detect cancer (up to 10 years ahead)

Imagine being armed with precautionary measures to fight a disease – like being vaccinated before the flu season arrives. What if we could have a similar kind of preparedness for a dangerous disease like cancer?

Turns out, it’s possible.

In what may be a landmark moment in cancer detection, researchers have unveiled a simple blood test capable of catching head and neck cancers up to ten years before symptoms show. This test, particularly aimed at cancers linked to the human papillomavirus (HPV), uses advanced genomic tools and machine learning to spot tiny fragments of tumor DNA circulating silently in the blood.

This breakthrough offers hope for early intervention, less aggressive treatments, and vastly improved outcomes. If validated and scaled up, it could transform how we screen, treat, and manage these cancers – shifting from late-stage, harmful interventions to early, less invasive care.

A recent study by the Harvard-affiliated Mass General Brigham system has introduced a groundbreaking blood test, called HPV-DeepSeek, which can detect HPV-associated head and neck cancers years before symptoms emerge. Unlike conventional methods that wait for a tumor to cause visible signs, this test works by scanning for DNA fragments shed by tumors into the bloodstream long before the disease becomes visible.

10 unusual body changes that could point to cancer

Belly fat burner: 7 carbs to help you lose visceral fat

The simple exercise that can add years to your life and keep you healthier as you age

Head and neck cancers include those affecting the throat (oropharynx), tonsils, base of tongue, and other surrounding areas. A significant fraction of these – especially in developed countries – are caused by the human papillomavirus (HPV). HPV is responsible for roughly 70% of oropharyngeal (throat) cancers in certain populations, making it a major health concern. Yet until now, there has been no reliable screening test for these cancers – unlike cervical cancer, where PAP smears and HPV tests are routine.

Because these cancers often produce few or no early symptoms, many are discovered late, after they have grown large or spread to lymph nodes. Detecting cancer long before signs appear could reduce the need for extensive surgeries, radiation, and chemotherapy, thereby lowering treatment side effects and improving survival.

The test was developed by a team at Mass General Brigham, particularly in the Mike Toth Head and Neck Cancer Research Center (Mass Eye and Ear). Their earlier work had shown that using only small portions of the HPV genome or more limited assays yielded reduced accuracy, especially for early or minimal disease. By contrast, HPV-DeepSeek’s “look broadly” approach improves detection, especially in early stages.

In follow-up validation, the researchers are applying the test to larger, blinded sample sets, including those from national repositories such as the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

The key principle is liquid biopsy – detecting fragments of tumor DNA circulating in the blood (often called circulating tumor DNA, ctDNA). But HPV-DeepSeek goes further: it uses whole-genome sequencing of the entire HPV genome, along with advanced machine-learning approaches, to find even minute viral DNA fragments and other biomarkers.

In their studies, researchers tested archived blood samples collected years before diagnosis. Among 28 individuals who later developed HPV-associated head and neck cancer, HPV-DeepSeek detected HPV DNA in 22 of them, and all 28 healthy control samples tested negative. By improving the algorithm with machine learning, they achieved a detection rate of 27 out of 28 in follow-ups, including in samples as old as 10 years before diagnosis.

The test also shows very high specificity (i.e., few false positives) and sensitivity (i.e., true positives) reported as 99% for both inpatients at their first clinical presentation.

Need for large clinical trials: While initial results are promising, broad use will require validation in diverse populations, across geographies and demographics.

False positives/negatives: Though specificity and sensitivity are high in these studies, no test is perfect. There remains a risk of false alarms or missed disease.

Follow-up protocols: If the test returns a positive result in an asymptomatic person, how doctors should follow up (imaging, biopsies, frequency) must be carefully worked out.

Cost and accessibility: Whole-genome sequencing and advanced analytics may be expensive. Scaling to routine screening, especially in low-resource settings, will be a challenge.

Applicability only to HPV-driven cancers: This test is specific for cancers linked to HPV. It does not yet address head and neck cancers from other causes (like tobacco, alcohol).

If HPV-DeepSeek or similar blood tests become clinically available, the landscape of cancer care could shift. Some possible impacts:

Earlier treatment: Detecting tumors at their tiniest stages may allow less invasive treatments, preserving function (speech, swallowing) and reducing side effects.

Better survival and quality of life: Earlier intervention often leads to better outcomes and fewer long-term complications.

Rethink screening guidelines: HPV-DeepSeek might become part of screening in populations at risk (e.g., people with known HPV infection or those with risk factors).

Cost savings: While upfront costs may be high, preventing advanced disease and complications can reduce overall health system expenses.

Increased research for other cancers: Success here may spur similar approaches for other cancers where blood tests are not yet available.

Researchers are actively expanding studies to confirm results in larger, more diverse populations. Meanwhile, coupling this approach with other liquid biopsy techniques and artificial intelligence may unlock early detection for many cancer types.

In practical terms, it may be some years before HPV-DeepSeek becomes routine in clinical practice. But its promise, that a simple blood draw might reveal cancer long before symptoms, marks a hopeful step toward a future where cancers are caught before they take hold.